Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Q1FY24 Financial Results07-08-2023
07-08-2023
Q1FY24 Quarterly Result Announced for Gland Pharma Ltd.
Pharmaceuticals company Gland Pharma announced Q1FY24 results: Revenue from operations of Rs 12,087 million in Q1FY24 compared to Rs 8,569 million in Q1FY23, up 41% YoY Gross Profit of Rs 7,558 million in Q1FY24 comapred to Rs 4,828 million in Q1FY23, up 57% YoY EBITDA of Rs 2,982 million in Q1FY24 comapred to Rs 2,699 million in Q1FY23, up 10% YoY EBITDA Margin of 25% in Q1FY24 comapred to 31% in Q1FY23 PBT of Rs 2,613 million in Q1FY24 comapred to Rs 3,085 million in Q1FY23, down 15% YoY PAT of Rs 1,941 million in Q1FY24 compared to Rs 2,292 million in Q1FY23, down 15% YoY Total Capex incurred during Q1FY24 was Rs 687 million Commenting on the results, Srinivas Sadu, MD & CEO, Gland Pharma said, “I am pleased to share that the efforts made for business recovery, after a challenging previous year, are yielding fruitful results. I would like to congratulate our team for their relentless efforts in launching 33 product SKUs during this quarter. The operating revenue for the quarter stood at Rs 12,087 million, a YoY growth of 41% with an EBITDA of Rs 2,982 million. The outcomes of the recently conducted US FDA inspections at three of our sterile facilities demonstrate our commitment to being a quality-focused and regulatory-compliant company. Maintaining an unwavering focus on quality and regulatory compliance establishes trust with our partners and will keep us in good stead in further strengthening our customer base.” Result PDF07-08-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Management
The Board has approved appointment of Mr. Prakash Vithal Baliga as Chief Operating Officer of the Company.07-08-2023
Gland Pharma Ltd - 543245 - Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2023.
Unaudited financial results of the Company for the quarter ended June 30, 202307-08-2023
Gland Pharma Ltd - 543245 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2023
The Board of Directors at its meeting held on August 07, 2023 has inter-alia approved the Unaudited financial results of the Company for the quarter ended June 30, 2023.07-08-2023
Gland Pharma shares jump 5% on zero observation from US FDA
A meeting of the board of directors of the company will be held on August 7, 2023, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2023.31-07-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call - Q1FY2428-07-2023
Gland Pharma Ltd - 543245 - Board Meeting Intimation for The Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2023.
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2023.27-07-2023
Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nippon Life India Trustee Ltd24-07-2023